Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology)
Drug Alias NameAnti-BCMA CAR-T cells抗B细胞成熟抗原（BCMA）CAR-T细胞疗法B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapyB细胞成熟抗原（BCMA）靶向嵌合抗原受体（CAR）T细胞疗法抗BCMA CAR-T细胞疗法
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsAnti-BCMA
TargetsTumor necrosis factor ligand superfamily member 13B-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesHuazhong University Of Science And Technology
China Registration ClassN/A

Develop Information

Active CompaniesHuazhong University Of Science And Technology
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A